I think that investors have relied on analyst reports (such as Roth & Edison) to put the trial result releases into perspective.
It would be interesting to know why VLA has ceased funding these reports. The target SP predictions have been a joke but the analysis has been quite good.
.
VLA Price at posting:
72.0¢ Sentiment: Buy Disclosure: Held
